ArticleJournal of virology2008
Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- LRRC15-CAR T Cells for the Treatment of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Oncolytic adenovirus type 11-induced ferroptosis of esophageal squamous cell carcinoma cells involves in mitochondrial impairment and the mTOR pathway.BMC cancer · 2026Article
- Defining diverse spike-receptor interactions involved in SARS-CoV-2 entry: Mechanisms and therapeutic opportunities.Virology · 2025Review
- Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway.Scientific reports · 2025Article
- The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma.American journal of cancer research · 2025Article
- Article
- Global impact of proteoglycan science on human diseases.iScience · 2023Review
- Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs.PLoS biology · 2023Article
- LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein.PLoS biology · 2023Article
- Review
- Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach.International journal of molecular sciences · 2022Article
- LRRC15 inhibits SARS-CoV-2 cellular entry in trans.PLoS biology · 2022Article
- Exploiting LRRC15 as a Novel Therapeutic Target in Cancer.Cancer research · 2022Review
- Identification and Validation of Hub Genes for Predicting Treatment Targets and Immune Landscape in Rheumatoid Arthritis.BioMed research international · 2022Article
- LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entrybioRxiv : the preprint server for biology · 2021Article
- Article
- DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma.Developmental cell · 2020Article
- Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer.Bioscience reports · 2020Article
- Accelerated parallel algorithm for gene network reverse engineering.BMC systems biology · 2017Article
- Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Adenoviruses for gene or oncolytic therapy are under development. Notable among these strategies is adenoviral delivery of the tumor suppressor p53. Since all therapeutics have limitations in certain settings, we have undertaken retroviral suppressor screens to identify genes conferring resistance to adenovirus-delivered p53. These studies identified the tumor antigen LRRC15, which is frequently overexpressed in multiple tumor types, as a repressor of cell death due to adenoviral p53. LRRC15, however, does not impede p53 function per se but impedes adenoviral infection. Specifically, LRRC15 causes redistribution of the coxsackievirus-adenovirus receptor away from the cell surface. This effect is manifested in less adenoviral binding to the surfaces of LRRC15-expressing cells. This discovery, therefore, not only is important for understanding adenoviral biology but also has potentially important implications for adenovirus-based anticancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.